Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pere Gines

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Clinics in Liver Disease|September 15, 2006
Hepatorenal syndromeAndrés Cárdenas, Pere Gines
Journal of Hepatology|July 4, 2012
Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practicePaolo Angeli, Pere Gines
Journal of Hepatology|May 19, 2022
Long-term albumin treatment in patients with cirrhosis and ascitesPaolo Caraceni, Alastair O'Brien, Pere Gines
Journal of Hepatology|September 19, 2025
Reply to: "From protocol to precision: The evolving diagnosis of hepatorenal syndrome" and "Plasma volume expansion in patients with cirrhosis, ascites and acute kidney injury: Enough, but not too much": Is it better to base care of patients on evidence even limited, or on opinions and good intentions?Paolo Angeli, Patrick S Kamath, Pere Gines
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 24, 2024
From prognostication to therapeutics: Four key questions to accelerate the development of therapeutics for patients with acute-on-chronic liver failureJennifer C Lai, S K Sarin, Pere Gines
BMJ (Clinical Research Ed.)|September 15, 2020
Hepatorenal syndrome: pathophysiology, diagnosis, and managementDouglas A Simonetto, Pere Gines, Patrick S Kamath
Journal of Hepatology|April 5, 2025
Reply to: Correspondence on "Variation in intention-to-treat survival by MELD subtypes: All models created for end-stage liver disease are not equal": MELD-Creatinine: The C(r)at is out of the bagSumeet K Asrani, Patrick S Kamath, Pere Gines
Hepatology (Baltimore, Md.)|February 21, 2013
Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complicationsRita Garcia-Martinez, Paolo Caraceni, Mauro Bernardi, et al.
Hepatology (Baltimore, Md.)|October 6, 2023
Noninvasive assessment of hepatic decompensationMaja Thiele, Stine Johansen, Mads Israelsen, et al.
Journal of Hepatology|June 15, 2010
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosisFlorence Wong, Pere Gines, Hugh Watson, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Clinics in Liver Disease|September 15, 2006
Hepatorenal syndromeAndrés Cárdenas, Pere Gines
Journal of Hepatology|July 4, 2012
Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practicePaolo Angeli, Pere Gines
Journal of Hepatology|May 19, 2022
Long-term albumin treatment in patients with cirrhosis and ascitesPaolo Caraceni, Alastair O'Brien, Pere Gines
Journal of Hepatology|September 19, 2025
Reply to: "From protocol to precision: The evolving diagnosis of hepatorenal syndrome" and "Plasma volume expansion in patients with cirrhosis, ascites and acute kidney injury: Enough, but not too much": Is it better to base care of patients on evidence even limited, or on opinions and good intentions?Paolo Angeli, Patrick S Kamath, Pere Gines
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 24, 2024
From prognostication to therapeutics: Four key questions to accelerate the development of therapeutics for patients with acute-on-chronic liver failureJennifer C Lai, S K Sarin, Pere Gines
BMJ (Clinical Research Ed.)|September 15, 2020
Hepatorenal syndrome: pathophysiology, diagnosis, and managementDouglas A Simonetto, Pere Gines, Patrick S Kamath
Journal of Hepatology|April 5, 2025
Reply to: Correspondence on "Variation in intention-to-treat survival by MELD subtypes: All models created for end-stage liver disease are not equal": MELD-Creatinine: The C(r)at is out of the bagSumeet K Asrani, Patrick S Kamath, Pere Gines
Hepatology (Baltimore, Md.)|February 21, 2013
Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complicationsRita Garcia-Martinez, Paolo Caraceni, Mauro Bernardi, et al.
Hepatology (Baltimore, Md.)|October 6, 2023
Noninvasive assessment of hepatic decompensationMaja Thiele, Stine Johansen, Mads Israelsen, et al.
Journal of Hepatology|June 15, 2010
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosisFlorence Wong, Pere Gines, Hugh Watson, et al.
Pageof 5